TP53 and non-small cell lung carcinoma: Analyzing the IMpower 150 trial showed that PFS (14.3 vs. 4.6 vs. 4.2 months) and OS (30.6 vs. 11.7 vs. 9.5 months) in the first-line ABCP regimen were significantly longer than in ACP or BCP regimens.34 Consistently, research by Sun et al. indicated that PFS (18.7 vs. 6.1 vs. 6.8 months, p < .0001) of KRASm NSCLC with TP53 mutation were significantly longer in ICI combined with chemotherapy than those in the chemotherapy alone or chemotherapy combined with antivascular therapy.33